Skip to main content

Advertisement

SpringerLink
Log in

Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?

  • Special Feature
  • From improved survival to potential cure in patients with metastatic breast cancer
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Unlike early stage breast cancer, metastatic breast cancer (MBC) is generally considered incurable except for a small number of patients with oligometastatic disease. The goal of treatment of MBC should be the prolongation of life and improvement of symptoms and quality of life. The prognoses of patients with MBC, however, have been improved with the introduction of newer, more effective agents. Therefore, the clinical question arises whether MBC patients can be cured with these new therapeutic agents. However, there are a couple of problems in tackling this question, including the duration of follow-up and the presence of strong adjuvant therapy. Firstly, most trials in MBC have a relatively short follow-up; long-term surveillance (>3–5 years) is exceptional, so little is known about the definitive outcome and the exact proportion of long-term survivors. Secondly, most of the patients have received pre- or postoperative adjuvant therapy. The cancer cells at metastatic sites are considered to be relatively resistant to the agents used in metastatic settings. Promisingly, a number of novel therapeutic agents including antibody–drug conjugates, irreversible small molecule HER2-tyrosine inhibitors, and HER2 dimerization inhibitors show promise in the treatment of HER2-overexpressing MBC, as well as PARP-1 [poly(ADP-ribose) polymerase-1] inhibitors for triple-negative breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456–63.

    Article  PubMed  Google Scholar 

  2. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104(8):1742–50.

    Article  PubMed  Google Scholar 

  3. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22(16):3302–8.

    Article  PubMed  Google Scholar 

  4. Shigematsu H, Kawaguchi H, Nakamura Y, Tanaka K, Shiotani S, Koga C, et al. Significant survival improvement of patients with recurrent breast cancer in the periods 2001–2008 vs. 1992–2000. BMC Cancer. 2011;11:118.

    Article  PubMed  Google Scholar 

  5. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456–63.

    Article  PubMed  Google Scholar 

  6. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas MD Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104(6):1158–71.

    Article  PubMed  CAS  Google Scholar 

  7. Network NCC. 2008 NCCN clinical practice guidelines in oncology: breast cancer, version 2. 2008

  8. Kataja V, Castiglione M, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii11–3.

    Article  PubMed  Google Scholar 

  9. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–9.

    Article  PubMed  Google Scholar 

  10. Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer. 1996;32A(11):1876–87.

    Article  PubMed  CAS  Google Scholar 

  11. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–205.

    PubMed  CAS  Google Scholar 

  12. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer. 1999;85(1):104–11.

    Article  PubMed  CAS  Google Scholar 

  13. Decker DA, Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, O’Fallon JR. Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA. 1979;242(19):2075–9.

    Article  PubMed  CAS  Google Scholar 

  14. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339(14):974–84.

    Article  PubMed  CAS  Google Scholar 

  15. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group. Efficacy and Tolerability study. J Clin Oncol. 2000;18(22):3748–57.

    PubMed  CAS  Google Scholar 

  16. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18(7):1399–411.

    PubMed  CAS  Google Scholar 

  17. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–9.

    Article  PubMed  CAS  Google Scholar 

  18. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  PubMed  CAS  Google Scholar 

  19. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–74.

    Article  PubMed  CAS  Google Scholar 

  20. Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110(5):973–9.

    Article  PubMed  Google Scholar 

  21. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN, et al. Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000. Cancer. 2004;100:44–52.

    Article  PubMed  Google Scholar 

  22. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol. 1998;16(7):2401–8.

    PubMed  CAS  Google Scholar 

  23. Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984;1:588–91.

    Article  PubMed  CAS  Google Scholar 

  24. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.

    Article  PubMed  CAS  Google Scholar 

  25. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27:5529–37.

    Article  PubMed  CAS  Google Scholar 

  26. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–27.

    Article  PubMed  CAS  Google Scholar 

  27. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Peinkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med. 2006;355:2733–43.

    Article  PubMed  CAS  Google Scholar 

  28. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544–52.

    Article  PubMed  CAS  Google Scholar 

  29. Baselga J, Gelmon KA, Verma S, Wadley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138–44.

    Article  PubMed  CAS  Google Scholar 

  30. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErrbB2-positive breast cancer. J Clin Oncol. 2010;28:1301–7.

    Article  PubMed  CAS  Google Scholar 

  31. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab–DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398–405.

    Article  PubMed  CAS  Google Scholar 

  32. O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205–14.

    Article  PubMed  Google Scholar 

  33. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27:1999–2006.

    Article  Google Scholar 

  34. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus carecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533–43.

    Article  PubMed  CAS  Google Scholar 

  35. Johnston S, Pippen J Jr, Pivot S, Lichinitser M, Sadeghi S, Gomez HL, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538–46.

    Article  PubMed  CAS  Google Scholar 

  36. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  PubMed  CAS  Google Scholar 

  37. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29–36.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan

    Shinji Ohno, Kimihiro Tanaka, Chinami Koga, Sumiko Nishimura, Hiroshi Yamaguchi, Hidetoshi Kawaguchi, Tomoyuki Yoshiyama & Yoshiaki Nakamura

Authors
  1. Shinji Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimihiro Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chinami Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sumiko Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hidetoshi Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomoyuki Yoshiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshiaki Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinji Ohno.

About this article

Cite this article

Ohno, S., Tanaka, K., Koga, C. et al. Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?. Breast Cancer 19, 212–217 (2012). https://doi.org/10.1007/s12282-011-0277-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-011-0277-2

Keywords

Search

Navigation